-
-
Major Depressive Disorder – where are we falling short?
-
Posted in Sponsored Feature
-
23rd Jul 2020
-
Professor Ramin Nilforooshan
-
-
Clinical perspectives on MAVENCLAD® (cladribine 10mg tablets), for highly active relapsing multiple sclerosis (MS), and real-world experiences from members of the multidisciplinary MS team
-
Posted in Sponsored Feature,Supplements
-
07th May 2019
-
This article was initiated, developed and funded by Merck
-
-
Viewpoints: News from the ILAE British Chapter Annual Scientific Meeting
-
Posted in Courses & Conferences,Online First,Sponsored Feature
-
14th Dec 2018
-
Download our 8 page newsletter, produced in association with LivaNova
-
-
Challenging the Status Quo
-
Posted in Online First,Sponsored Feature
-
07th Dec 2017
-
Sponsored feature: Highlights from the National Epilepsy Nurse Meeting
-
-
The Missing Pieces: Identifying the gaps in care and conversations in MS
-
Posted in Online First,Special Feature,Sponsored Feature
-
10th Jul 2017
-
Developed and funded by Sanofi Genzyme
-
-
Sponsored Article
-
Posted in Australia/New Zealand,Online First,Special Feature,Sponsored Feature
-
01st Feb 2017
-
STADA Australia continues to innovate in Parkinson’s Disease with MOVAPO® pre-filled syringes (PFS) Parkinson’s Disease is a surprisingly prevalent condition with an estimated 10 million people worldwide and roughly 70,000 Australians (1 in every 340 people) suffering from the condition.1 It is the second most prevalent neurological condition exceeded only by dementia. It is more common […]
-
-
Peripheral Neuropathy: What It Is and What You Can Do to Feel Better
-
Posted in Book Reviews,Industry News,Sponsored Feature
-
08th Dec 2016
-
Book News
-
-
ILAE conference report
-
Posted in Courses & Conferences,Sponsored Feature,Supplements
-
11th Nov 2015
-
News from the recent ILAE meeting
-
-
In Parkinson’s disease, patients may suffer from delayed ON as well as wearing OFF – which is more important?
-
Posted in Courses & Conferences,Sponsored Feature
-
02nd Jun 2015
-
Report from Britannia Pharmaceuticals on their plenary session on PD treatment, held at the 9th CONy Congress in Budapest, Hungary, March 2015
-
-
Consensus meeting on the use of perampanel▼ as adjunctive therapy in clinical practice: recommendations from an expert panel
-
Posted in Sponsored Feature,Supplements
-
15th Apr 2015
-
Summary Perampanel has a novel mode of action based on a rational hypothesis of seizure initiation and spread. This can be considered when discussing the possibility of initiating perampanel treatment in patients with partial onset seizures who have failed to gain control with other AEDs. Perampanel is an easy to use antiepileptic treatment that, based […]
